1 Science Powerhouse To Own for the Next Decade
Thermo Fisher Scientific has a knack for thriving even in challenging markets. While the company isn’t entirely immune to today’s global headwinds, slower biopharmaceutical spending, tighter budgets in academic labs, and muted demand in China, it has weathered the storm far better than most of its peers.
The reason?
A combination of unmatched scale,
» Read more about: 1 Science Powerhouse To Own for the Next Decade »
Read More
1 Coffee Shop Chain Set to Challenge Starbucks
Retail growth stories tend follow predictable patterns of early excitement, rapid growth, and then the inevitable pains of scaling. Every once in a while, though, a company breaks the mold in subtle yet important ways. Dutch Bros might well be that company and arguably is much more than a coffee chain.
Walking into a relatively new location in Phoenix last week,
» Read more about: 1 Coffee Shop Chain Set to Challenge Starbucks »
Read More
Is Your Favorite Pharmacy About To Go Belly Up?
Walgreens Boots Alliance stands at a critical juncture in the company’s 170-year history with revenues of $147 billion but a market capitalization of just $7 billion.
A heavily burdened balance sheet has been the prime culprit of the stock’s downfall but, under new CEO Tim Wentworth, management is undertaking an ambitious realignment aimed at stabilizing the core pharmacy business while taking the chop to some of its healthcare investments.
» Read more about: Is Your Favorite Pharmacy About To Go Belly Up? »
Read More
30% Upside for Leader in Market Growing 30% Annually?
Renowned e-signature company DocuSign, Inc. (NASDAQ:DOCU) has got firmly back on track after some turbulence in 2021 and 2022 when the company’s share price declined by more than 75%.
The recent stock performance has fared much better, begging the question where is the ceiling for this once hot stock?
» Read more about: 30% Upside for Leader in Market Growing 30% Annually? »
Read More
Will Buffett’s 23-Quarter Streak Start Again?
For more than half a decade, Warren Buffett’s Berkshire Hathaway accumulated the same stock quarter after quarter, 23 straight times, to be exact. Then, without warning, the buying stopped last year.
It wasn’t because Buffett lost faith in the company. In fact, his recent moves suggest he’s been biding his time, waiting for the numbers and the price to line up again.
» Read more about: Will Buffett’s 23-Quarter Streak Start Again? »
Read MoreThe Burst
Nvidia Just Matched Microsoft in Value, So Is It Still a Smart Buy?
Nvidia (NASDAQ: NVDA) just pulled off something extraordinary, again. Fiscal Q1 2026 numbers weren’t just good, they were extraordinary.
Management reported a top line of $44.1 billion, up 69% from the same time last year, and 12% higher than the previous quarter. Net income was an eye-popping $18.8 billion, and that’s in spite of a $4.5 billion charge tied to new U.S.
» Read more about: Nvidia Just Matched Microsoft in Value, So Is It Still a Smart Buy? »
Read MoreThe Spotlight
The Pet Care Powerhouse Flying Under Wall Street’s Radar
With the S&P 500 having advanced by about 23.7% year-to-date, deals among large-cap companies appear few and far between.
One stock that may be attractive, however, is Idexx Laboratories (NASDAQ:IDXX). This company specializes in veterinary diagnostic devices as well as poultry and livestock testing, among other animal-care essentials. Idexx also makes water testing supplies to monitor and maintain water quality.
» Read more about: The Pet Care Powerhouse Flying Under Wall Street’s Radar »
Read MoreThe Daily
Why Kratos and AeroVironment Are Suddenly Moving Like Tech Stocks
-
Kratos has successfully transitioned from experimental testing to full-scale mass production of hypersonic systems and tactical drones.
-
New federal regulations banning foreign competitors have created a protected domestic market for AeroVironment and its commercial drone systems.
» Read more about: Why Kratos and AeroVironment Are Suddenly Moving Like Tech Stocks »